Vaxart, Inc. – Press Releases

Search

Year

August 30, 2024

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024 , the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its

August 28, 2024

PDF Version

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

- Data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - - Results suggest that Vaxart’s mucosal vaccine platform holds promise in enabling a novel,

August 08, 2024

PDF Version

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

BARDA Project NextGen contract to support a Phase 2b trial potentially positions Vaxart’s oral pill vaccine platform as a next-generation approach to combating COVID-19 and future pandemic threats Solid financial position enables Vaxart to execute on multiple regulatory and clinical

August 02, 2024

PDF Version

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August

June 17, 2024

PDF Version

Vaxart Provides Business Update

— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif.

June 13, 2024

PDF Version

Vaxart Announces $40 Million Underwritten Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share.

June 13, 2024

PDF Version

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH SAN FRANCISCO, Calif. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc.

May 23, 2024

PDF Version

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024 , the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common

May 13, 2024

PDF Version

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved

May 07, 2024

PDF Version

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13,

Pagination

Current page 1
Page 2
Next page
Last page

Press Releases.

Search